Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK3 | O75914 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.45 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.45 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.45 |
| ▸ | WEE1 | P30291 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 14/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553633 | 0.85 | PAK3 (0.45) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL15035975 | 0.76 | TNK2 (0.45) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL15035090 | 0.76 | PAK3 (0.45) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL14681940 | 0.71 | TNK2 (0.41) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL13553488 | 0.70 | PAK3 (0.50) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL13553868 | 0.70 | PAK4 (0.57) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL15785354 | 0.70 | PAK4 (0.57) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL15041686 | 0.69 | PAK4 (0.52) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL13553939 | 0.68 | PAK1 (0.43) | PAK4PAK1PKN1WEE1TNK2 | |
| SCHEMBL15036435 | 0.67 | WEE1 (0.52) | PAK3PAK4LIMK1LIMK2PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | PAK3 4/4885PAK4 6/4885LIMK1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.